ReviewMedComm2025
Transforming Growth Factor-β Pathway: Biological Functions and Therapeutic Targets.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Exploring betanin regulatory impact on TGF-β and PI3K/AKT pathways in oral cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bone morphogenetic protein 5 as a potential diagnostic and prognostic biomarker in lung adenocarcinoma.Translational cancer research · 2026Article
- BCR-ABL1 Drives Transcriptional Reprogramming of Chronic Myeloid Leukemia Cells for Immune Evasion Through C/EBPβ.MedComm · 2026Article
- Synergistic Interactions Between Medicinal Plant Bioactive and Standard Chemotherapy in Gastric Cancer: Preclinical Evidence and Translational Pitfalls.Biomedicines · 2026Review
- Decoding osteosarcoma from heterogeneity to precision therapy.Discover oncology · 2025Review
- Phenotypic switching of vascular smooth muscle cells: a central mechanism in vein graft intimal hyperplasia.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer progression is often driven by aberrant cell growth and genetic mutations, leading to metastasis. The transforming growth factor-beta (TGF-β) pathway, a key regulator of cellular growth and differentiation, exhibits dual roles in cancer by initially acting as a tumor suppressor and later promoting tumor progression and metastasis. Natural compounds, recognized for their diverse bioactivities and low toxicity, have shown potential in targeting cancer-related pathways, including TGF-β signaling. This review examines the therapeutic potential of natural products in modulating TGF-β signaling and their anticancer effects across various cancer types. We evaluated relevant preclinical and clinical studies assessing the impact of natural products on TGF-β modulation and cancer progression. Natural compounds from sources such as plants impact TGF-β signaling, influencing processes like cell proliferation, apoptosis, and angiogenesis. Key compounds reviewed include ginsenosides, halofuginone, and epigallocatechin gallate, demonstrating significant anticancer activity via TGF-β pathway modulation. These findings suggest natural products may serve as complementary therapies in cancer treatment by targeting TGF-β signaling, potentially improving patient outcomes. Continued research and clinical evaluation are necessary to integrate these compounds into conventional cancer therapies, aiming to offer safer, cost-effective options that enhance quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.